Pharmaceutical giant Eli Lilly alleges the companies are selling off-brand versions of its best-selling diabetes and ...

As the FDA cracks down on compounded GLP-1 drugs like semaglutide and tirzepatide, the market for GLP-1 supplements is taking ...

Some experts say oral versions of popular weight-loss drugs such as Wegovy could offer people more flexibility and ...

Ascletis is taking a low and slow approach to oral GLP-1 dose titration in a phase 2a test after getting a look at clinical ...

GLP-1 medications like Ozempic may help reduce alcohol cravings and support recovery—especially when combined with therapy ...

After selling off a portion of its diabetes care business last year, Ypsomed is now fully exiting the diabetes care business ...

Spending on Ozempic, Wegovy and other similar prescriptions soared 500 percent in five years, according to a research letter.

Dispensations of tirzepatide and semaglutide increased significantly in recent years while the use of other glucose-lowering ...

TNF and Renova Health are set to use AI and ML for the identification of high-risk subjects who could benefit from GLP-1 ...

Nearly two years after reporting successful results from a phase 3 trial of its oral version of injected obesity treatment ...

Let's look at why this news could be a game-changer for Eli Lilly and its stock.

A daily weight loss pill being tested by Eli Lilly could work as well as its GLP-1 injection counterparts like Ozempic, ...